Simulated Synovial Fluid for Reproducible Cell Therapy Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis are limited due to the variability of patient-specific osteoarthritis environments, making it challenging to evaluate the efficacy of cell therapies, which respond differently to intra-articular injections. There is a need for a simulated synovial fluid that can provide reproducible and predictive outcomes for therapeutic efficacies.
Innovation Solution
A simulated synovial fluid composition comprising cytokines such as bFGF, G-CSF, HGF, MIG, and MCP-1, along with hyaluronic acid and human serum albumin, which mimics the viscoelastic properties of patient-derived synovial fluid, including viscosity and moduli, to simulate the osteoarthritis environment for testing cell therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If patient-specific synovial fluid is used to evaluate cell therapy efficacy, then the evaluation reflects individual patient responses, but the variability among patients makes it difficult to establish reproducible and predictive outcomes
Solution Approach 1:
The patent creates a simulated synovial fluid composition that copies the essential components and properties of patient-specific synovial fluid. By replicating the biochemical environment (cytokines, growth factors, extracellular matrix components) in a standardized formulation, the invention enables reproducible cell therapy evaluation without the variability inherent in using actual patient samples. This allows predictive outcomes to be established while maintaining the biological relevance of the synovial fluid environment.
Solution Approach 2:
The invention transforms the variable parameters of patient-specific synovial fluid into controlled, standardized parameters. By defining specific concentrations of cytokines (IL-1β, TNF-α), growth factors (FGF-2, TGF-β), and extracellular matrix components (hyaluronic acid, collagen) in the simulated composition, the patent converts the natural variability into a consistent, reproducible formulation that maintains biological fidelity while enabling standardized testing.
2Measurement precision
If actual patient synovial fluid is used for testing, then the test environment is biologically accurate, but the complexity and variability of individual patient samples complicate standardization and reproduction of results
Solution Approach 1:
The patent extracts the essential biological components from complex patient synovial fluid samples to create a simplified yet biologically accurate simulated composition. By identifying and isolating the key constituents (specific cytokines, growth factors, and extracellular matrix components) that drive cell therapy responses, the invention removes the unnecessary complexity and variability of individual patient samples while retaining the critical biological functions needed for accurate testing.
Solution Approach 2:
The simulated synovial fluid composition applies local quality by concentrating specific bioactive components at defined concentrations rather than using the heterogeneous mixture found in patient samples. Each component (cytokines, growth factors, matrix components) is present at optimized levels that replicate the local biological environment's effect on cells, providing biological accuracy without the complexity of full patient sample variability.
3Stability of the object's composition
If standardized simulated synovial fluid is developed, then reproducible outcomes can be achieved, but the composition must accurately mimic the complex biochemical properties of natural synovial fluid
Solution Approach 1:
The patent employs composite materials by combining multiple purified biochemical components (cytokines, growth factors, extracellular matrix components) in a standardized formulation. This composite approach allows each component to be precisely controlled for concentration and purity, ensuring reproducibility, while collectively mimicking the complex biochemical properties of natural synovial fluid. The composite nature enables standardization without sacrificing biological fidelity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The simulated synovial fluid effectively replicates the viscoelastic properties of patient-derived synovial fluid, allowing for reproducible and predictive cellular responses in cell therapy assays, thereby advancing the evaluation and development of osteoarthritis treatments.
Implementation Method 1
mimics the viscoelastic properties of patient-derived synovial fluid, including viscosity and moduli
Implementation Method 2
The composition can include two or more cytokines, and one or more of keratan sulfate, chondroitin sulfate, or hyaluronic acid
Data Source
AI summary
An exemplary embodiment of the present disclosure provides a composition comprising two or more cytokines, and one or more of keratan sulfate, chondroitin sulfate, or hyaluronic acid. The composition can simulate a fluid from a patient. The simulated fluid has a viscosity, a storage modulus, and a loss modulus similar to that of patient-derived synovial fluid. A method for making a composition for simulating a fluid from a patient is also disclosed. The method includes creating a mixture comprising two or more cytokines, and one or more of keratan sulfate, chondroitin sulfate, or human serum albumin. The method also includes adding a low molecular weight hyaluronic acid to the mixture, adding a high molecular weight hyaluronic acid to the mixture, and incubating the mixture for a predetermined time at a temperature ranging from approximately 0° C. to approximately 10° C.